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Abstract
Background: The urgent medical need for innovative approaches to control influenza is emphasized by the widespread
resistance of circulating subtype H1N1 viruses to the leading antiviral drug oseltamivir, the pandemic threat posed by the
occurrences of human infections with highly pathogenic avian H5N1 viruses, and indeed the evolving swine-origin H1N1
influenza pandemic. A recently discovered class of human monoclonal antibodies with the ability to neutralize a broad
spectrum of influenza viruses (including H1, H2, H5, H6 and H9 subtypes) has the potential to prevent and treat influenza in
humans. Here we report the latest efficacy data for a representative antibody of this novel class.
Methodology/Principal Findings: We evaluated the prophylactic and therapeutic efficacy of the human monoclonal
antibody CR6261 against lethal challenge with the highly pathogenic avian H5N1 virus in ferrets, the optimal model of
human influenza infection. Survival rates, clinically relevant disease signs such as changes in body weight and temperature,
virus replication in lungs and upper respiratory tract, as well as macro- and microscopic pathology were investigated.
Prophylactic administration of 30 and 10 mg/kg CR6261 prior to viral challenge completely prevented mortality, weight loss
and reduced the amount of infectious virus in the lungs by more than 99.9%, abolished shedding of virus in pharyngeal
secretions and largely prevented H5N1-induced lung pathology. When administered therapeutically 1 day after challenge,
30 mg/kg CR6261 prevented death in all animals and blunted disease, as evidenced by decreased weight loss and
temperature rise, reduced lung viral loads and shedding, and less lung damage.
Conclusions/Significance: These data demonstrate the prophylactic and therapeutic efficacy of this new class of human
monoclonal antibodies in a highly stringent and clinically relevant animal model of influenza and justify clinical
development of this approach as intervention for both seasonal and pandemic influenza.
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Introduction
A novel class of human monoclonal antibodies against influenza
has been recently discovered [1]. These antibodies bind to the
membrane-proximal stem of haemagglutinin, the major viral
surface protein, and neutralize the influenza virus by blocking its
fusion with the host cell [2]. A panel of antibodies with a similar
mode of action was reported subsequently by Sui et al. [3]. Due to
the high conservation of their recognition site, this class of
antibodies has shown the ability to neutralize a broad spectrum of
influenza subtypes, including H1, H2, H5, H6 and H9 [1], and
can be expected to also neutralize viruses from subtypes H4, H8,
H11–H14 and H16, as well as their future antigenic drift variants
[2]. One of these antibodies, CR6261, was investigated in mice
and shown to be protective when given before and after lethal
challenges with H1N1 and H5N1 virus, suggesting that it has
potential as the first-ever broad-spectrum monoclonal antibody for
prophylaxis and treatment of influenza virus infections [1].
According to the World Health Organization, seasonal
influenza causes up to 500,000 deaths worldwide each year [4].
Immunologically naı¨ve infants, immunocompromised individuals
and the elderly are particularly susceptible to illness caused by
seasonal influenza viruses, with 90% of deaths occurring in the
latter group [4,5]. In addition, subtypes of influenza A viruses that
have not previously circulated among humans occasionally cross
from animal reservoirs, raising the spectre of a pandemic.
Over the past decade, the most prominent pandemic threat
appeared to be posed by highly pathogenic avian influenza viruses
of subtype H5N1. However, it was a new strain of human H1N1
that emerged in Mexico and the United States in March and April
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2009 and rapidly spread across the globe that caused the WHO to
declare a pandemic on June 11th [6,7]. Although the virulence of
this virus is currently moderate, particularly compared to the case
fatality rate of over 60% of human H5N1 infections, this may
change over time. Meanwhile, the threat from highly pathogenic
avian H5N1 viruses persists as they continue to circulate and
evolve in bird populations.
Preventive vaccination has historically been the primary means
of influenza control, but this approach has important limitations.
Vaccines typically elicit a potent neutralizing antibody response
only to the specific viral strains they contain, and closely related
viruses [8,9]. Furthermore, influenza vaccines have suboptimal
immunogenicity and efficacy in the groups at highest risk of severe
disease: the very young, the elderly and immunocompromised
individuals [10].
The current therapeutic regimen for influenza A is limited to
two classes of drugs: the adamantanes (amantadine and rimanta-
dine) and the neuraminidase inhibitors (oseltamivir and zanami-
vir). Adamantanes rapidly elicit viral resistance, and resistance
rates are high among H3N2 viruses and certain clades of H5N1
viruses [11–14]. The use of oseltamivir, the leading antiviral
influenza drug, has been limited by the sudden and widespread
emergence of resistance among circulating H1N1 influenza strains
[15,16]. Oseltamivir resistance has also been observed during
treatment of H5N1 infection [17,18]. Zanamivir is still effective
against H1N1 viruses and resistance to this drug is less likely to
arise [19]. However, its use is limited to patients who can actively
use an inhaled drug, which excludes young children, impaired
older adults, or patients with underlying airway disease [16]–once
again, the group of patients most vulnerable to serious complica-
tions from influenza infection.
In the absence of reliable antiviral drugs and vaccines,
development of alternative strategies for influenza prophylaxis
and therapy is urgently required. In order to assess whether
CR6261 may be a viable option for human treatment, we
evaluated the prophylactic and therapeutic efficacy of this human
monoclonal antibody in a highly stringent lethal H5N1 influenza
ferret model. The ferret is the most suitable disease model for
human influenza infection as it displays very human-like disease
[20–22].
Results
Prophylactic Efficacy of CR6261 against H5N1 Challenge
Four groups of 6 ferrets each received 30, 10, 3 or 1 mg/kg
CR6261 via an intravenous injection and were challenged the next
day with the highly pathogenic avian A/Indonesia/5/2005
(H5N1) virus. A control group of 6 ferrets received 30 mg/kg of
the irrelevant isotype-matched antibody CR3014.
All ferrets that received 30 or 10 mg/kg CR6261 survived,
compared to only 33.3% of the control animals (Figure 1A). A
further reduction of the dose to 3 mg/kg was clearly correlated
with a lower survival rate of 66.7%. Though not statistically
significant different from survival observed in control animals,
there is a 50% mortality reduction. The lowest dose of 1 mg/kg
CR6261 was not associated with survival benefit compared to
control animals. Survival times differed significantly between
groups receiving 30 or 10 mg/kg CR6261 and the control group
(p = 0.020).
Moribund animals showed general depression, anorexia and
lethargy, and exhibited clinical signs of respiratory disease,
including dyspnoea. Animals treated at efficacious dose levels (30
and 10 mg/kg) did not loose body weight, whereas the mean
weight loss in the control group was 10.5% by the time the ferrets
died or were euthanized (Figure 1B). An exception was one control
ferret that succumbed to infection within 48 hours after challenge
and lost hardly any weight before. Ferrets that received 3 or 1 mg/
kg CR6261 showed similar declines in body weight as the control
animals.
One day after challenge the maximum body temperature was
observed; for each ferret the maximum body temperature is
depicted in figure 1C. The groups treated with 30 or 10 mg/kg
had mean temperatures of 39.4uC and 40.7uC, respectively, which
were significantly lower than the mean of 41.7uC observed in the
control group (p,0.001 and p = 0.015, respectively). The mean
temperature observed in animals treated with the lower doses of
CR6261 (41.3uC and 41.5uC for 3 and 1 mg/kg, respectively) did
not differ significantly from the control group.
The mean temperature in animals observed 3 days before
challenge was similar across the 5 groups, ranging from 37.6uC to
38.4uC. Individual body temperature varied considerably within
one healthy ferret over 24 hours (standard deviation 0.7uC).
Ferrets treated with 30 or 10 mg/kg CR6261 did not shed
infectious virus in the upper respiratory tract at any time, whereas
animals in the control group did (Figure 1D). Treatment with 3
and 1 mg/kg did not prevent shedding, but reduced the
proportion of ferrets with infectious virus in nasal and/or throat
swabs.
After necropsy, all ferrets were assessed for viral load in the
lungs (figure 1E), and the animals that received 30 mg/kg CR6261
or control antibody were also assessed for viral load in the brain,
liver, spleen, blood and kidney. The levels of virus replication in
the lungs of ferrets treated with 30 and 10 mg/kg CR6261 were
3.9 and 2.9 log10 TCID50/g lower than that in the control group
(both p,0.001). No infectious virus was detected in any of the
other organs of the ferrets that received 30 mg/kg CR6261,
whereas infectious virus was found in the brain of 2, the liver of 3,
and the spleen of 5 of the 6 control animals (data not shown).
There was no significant difference in lung viral load in the groups
receiving 3 or 1 mg/kg CR6261 compared to the control group
(p = 0.74 and p = 0.91, respectively).
Histopathological results were in accordance with the findings
described above; animals that received 30 and 10 mg/kg CR6261
showed much less pulmonary lesions such as primary atypical
pneumonia, subacute bronch(iol)itis, emphysema and congestion, or
showed such lesions at a lower grade of severity, compared to animals
from the other groups. Bronchiolitis obliterans was not observed in
any animal that received 30 mg/kg CR6261. Compared to this
higher-dose group, animals that received 10 mg/kg CR6261 showed
more regenerative response (diffuse grey/red area and bronchioloal-
veolar hyperplasia) in the lungs, and more inflammatory changes in
the trachea. Pulmonary oedema was not observed in animals that
received 30 or 10 mg/kg CR6261, but was observed frequently in all
other groups. These findings were in agreement with mean lung
weights, which were lowest in the animals treated with 30 or 10 mg/
kg CR6261 (6.3 g and 7.6 g, respectively) and significantly lower in
this group than in control animals (15.0 g; both comparisons
p,0.001). No significant difference in lung weight was found
between the groups receiving 3 or 1 mg/kg CR6261 (14.1 g and
15.4 g, respectively) and the control group (15.0 g).
These findings show that, in a dose dependent way, prophy-
lactically administered CR6261 confers protection against lethal
H5N1 challenge, prevents morbidity and viral dissemination and
reduces pulmonary pathology.
Therapeutic Efficacy of CR6261 against H5N1 Challenge
To assess the therapeutic efficacy of the monoclonal antibody
CR6261, two groups of 10 ferrets were challenged as above and
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given 30 mg/kg of CR6261 either 4 or 24 hours later. A
comparator group of 10 ferrets received 30 mg/kg of the control
antibody 4 hours after challenge.
Survival rates in the groups receiving CR6261 at 4 and
24 hours after challenge were 100%, whereas only 20% of the
animals in the control group survived (p,0.001) (Figure 2A).
Mean decline in body weight at the end of the experiment was
6.2% in the group of ferrets that received CR6261 4 hours after
challenge (Figure 2B), which was significantly less (p = 0.025) than
the 10.1% observed in control animals. Animals treated 24 hours
post challenge showed a mean body weight loss of 8.4%, which
was not significantly different from the control animals (p = 0.427).
The group of ferrets treated with CR6261 4 hours post challenge
had a mean maximum temperature of 40.0uC, compared to
41.8uC in the control group (p,0.001). In line with the rapid rise
in temperature after challenge observed in the prophylaxis
experiment ferrets treated with CR6261 24 hours after challenge
showed a mean maximal temperature of 41.5uC before CR6261
was administered (p = 0.15 versus 41.8uC of the control group,
figure 2C).
Ferrets treated with CR6261 at 4 hours post challenge did not
shed infectious virus in the upper respiratory tract throughout the
study (figure 2D). In the group treated with CR6261 at 24 hours
post challenge, one ferret had a low concentration of infectious
virus (2.8 log10 TCID50) in the throat on day one, but no virus was
detected on subsequent days. In contrast, all animals in the control
group shed virus during one or more days. Accordingly, the mean
viral loads in the lungs of ferrets treated with CR6261 at 4 and
24 hours post challenge were considerably lower than that in the
control group (differences were 3.9 and 4.5 log10 TCID50/g,
respectively, both comparisons p,0.001; Figure 2E).
The lungs of animals that received CR6261 at 4 hours post
challenge showed less pulmonary lesions (alveolar oedema,
bronchiolitis obliterans, congestion, emphysema, bronchioloalveo-
Figure 1. Prophylactic efficacy of CR6261 against lethal H5N1 challenge. Groups of 6 ferrets received 30, 10, 3, or 1 mg/kg of mAb CR6261
or 30 mg/kg control mAb by intravenous injection and were challenged 24 hours later with 105 TCID50 of influenza A/Indonesia/5/2005 (H5N1).
Ferrets were monitored for 5 days or until death. Panel A: Kaplan–Meier survival probability curves. Panel B: Change in body weight at the end of
study (or at death if the event occurred earlier) expressed as percentage from baseline body weight. Panel C: Maximal body temperature observed
during the day after challenge. Panel D: Viral shedding of infectious virus in the upper respiratory tract. The graph shows the proportion of ferrets
alive with infectious virus detected in nasal and/or throat swabs. Panel E: Viral load in lung tissue as determined by virus titration on MDCK cells. Panel
F: lung weights as determined after necropsy. Dots in panels B, C, E and F represent individual animals; group means are indicated by the horizontal
lines.
doi:10.1371/journal.pone.0009106.g001
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lar hyperplasia and primary atypical pneumonia), or showed such
lesions at a lower grade of severity, compared to the lungs of
animals from the other two groups. Animals of the control group
were most affected by primary atypical pneumonia. These findings
were in accordance with the observation that the mean lung
weights of ferrets treated with CR6261 at 4 hours post challenge
were lower compared to the control group (5.7 g versus 14.9 g,
p,0.001; Figure 2F). Animals that received CR6261 at 24 hours
post challenge showed most regenerative response (bronchioloal-
veolar hyperplasia) in the lungs, suggesting damage to the lung
parenchyma with subsequent regenerative response. The mean
lung weight in this group was significantly higher than that of the
group receiving CR6261 at 4 hours post challenge (8.4 g versus
5.7 g), but lower than that of the control group (p,0.001).
From the study outset, one animal had been added to each of
the two treatment groups to be sacrificed for gross-pathology and
histology on lungs as soon as 50% of the control animals died. The
purpose was to test for possible bias due to differences in the timing
of death. Infectious virus titres in the lungs of the treated ferrets
sacrificed at day 3 were identical to those in treated animals
sacrificed at the end of the study (open circles in figure 2E).
Similarly, there were no differences in lung weight and pathology
between animals sacrificed at day 3 or after day 5 (figure 2F). This
indicates that the results were not biased by differences in the
timing of euthanasia or spontaneous death.
Discussion
CR6261 represents a new class of human monoclonal
antibodies that exhibits immediate and potent efficacy for the
prevention or treatment of influenza in a clinically relevant model
for severe disease. The results presented here also confirm
Figure 2. Therapeutic efficacy of CR6261 against lethal H5N1 challenge. Groups of 10 ferrets received 30 mg/kg mAb CR6261 by
intravenous injection either 4 or 24 hours after challenge with 105 TCID50 of influenza A/Indonesia/5/2005 (H5N1) virus. A control group of 10 ferrets
received 30 mg/kg of a control mAb 4 hours after challenge. Ferrets were monitored for 5 days or until death. Panel A: Kaplan–Meier survival
probability curves. Panel B: Change in body weight at the end of study (or at death if earlier) expressed as percentage from baseline weight. Panel C:
Maximal body temperature observed the day after challenge. Panel D: Viral shedding of infectious virus in the upper respiratory tract. The graph
shows the proportion of ferrets alive with infectious virus detected in nasal and/or throat swabs. Panel E: Viral load in lung tissue as determined by
virus titration on MDCK cells. Panel F: lung weights as determined after necropsy. Dots in panels B, C, E and F represent individual animals; group
means are indicated by horizontal lines. The open circles (panel E and F) indicate one additional ferret per CR6261 group that was euthanized at day 3
for virus isolation and pathology.
doi:10.1371/journal.pone.0009106.g002
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previously reported data demonstrating the prophylactic and
therapeutic efficacy of CR6261 in mice challenged with H5N1
influenza viruses. Together with the H1N1 challenged mice data
published earlier [1] these findings indicate that CR6261 is
effective across a broad spectrum of influenza viruses, including
seasonal and potentially pandemic strains.
Passive immunotherapy would be particularly beneficial for the
groups at highest risk of severe disease due to seasonal influenza–
the elderly and immuno-compromised–but may also be indispens-
able for the general public in the event of a pandemic disease
outbreak caused by high-risk pandemic candidates such as H2,
H5, H6 and H9.
Monoclonal antibodies against influenza viruses have been
studied for decades, but their potential–and thus development–as
‘passive’ immunotherapy for influenza has been inhibited by the
lack of monoclonal antibodies with broad neutralizing activity.
This lack is due to the tolerance of influenza virus for genetic
changes in the most immunogenic regions on its surface. The
recent discovery of broadly neutralizing human monoclonal
influenza antibodies [1] and the demonstrated efficacy of a
representative of this novel class of antibodies against lethal viral
challenge in a clinically relevant model, as presented in this paper,
create an opportunity for the prevention and treatment of
influenza infections, regardless of the causal strain. The possibility
of a potent and broadly neutralizing agent that would equip
clinicians and public health workers to deal effectively with the
influenza viruses of the future represents a paradigm shift in the
approach to influenza control.
Influenza illness observed in the ferrets infected with H5N1
virus in this study closely resembles influenza in humans with
H5N1 infection, who present with fever, cough, shortness of
breath, and radiological evidence of pneumonia [23]. Besides
respiratory symptoms, gastrointestinal symptoms such as diar-
rhoea, vomiting and abdominal pain are often present. In severe
cases, the pneumonia rapidly progresses to acute respiratory
distress syndrome and multiorgan failure. High viral loads,
extrapulmonary virus dissemination and hypercytokinaemia are
associated with fatal outcome (reviewed in [24–26]). Autopsies of
patients who succumbed to influenza A (H5N1) virus infection
have shown diffuse alveolar damage, patchy interstitial lympho-
plasmacytic infiltrates, bronchiolitis with squamous metaplasia and
pulmonary congestion with various degrees of haemorrhage
[27–29]. The clinical signs observed in the control animals of
this ferret study correspond to the most severe influenza pathology
in humans [23]. The efficacy of CR6261 in preventing these
clinical signs in the prophylactic and therapeutic ferret model
presented here, together with the efficacy shown in mice after
lethal challenges with different viruses, strongly indicate that
CR6261 can be expected to be efficacious against disease caused
by the other, less virulent viruses it neutralized in vitro [1].
In a meta-analysis of experimental influenza infection of
placebo-treated and untreated healthy volunteers, Carrat et al.
[30] studied 1280 participants who were challenged with either
influenza type H1N1, H3N2 or B. Interestingly, viral shedding was
highly correlated with the presence of clinical symptoms such as
fever, runny nose, sore throat, sneezing, cough and shortness of
breath. The authors concluded from their meta-analysis that
subjects with symptomatic illness shed virus in amounts 100 to
1000 fold higher than subjects who were not ill. The fact that
CR6261 after intravenous administration instantaneously reduces
viral shedding indicates that in man CR6261 might reduce clinical
symptoms in subjects infected with influenza virus. In addition,
studies in guinea pigs showed that a reduction in nasal wash titers
correlate with a decreased efficiency of viral transmission by
aerosol [31]. The ability of CR6261 to abolish shedding of virus in
pharyngeal secretions strongly suggests that antibodies like
CR6261 might prevent or reduce virus spreading at the onset of
an epidemic influenza outbreak in nursing homes or in case of a
pandemic.
In this study, we assessed the efficacy of the human monoclonal
antibody CR6261 against a highly pathogenic avian H5N1 virus,
as this provides a stringent disease model for severe influenza.
However, the potential use of this antibody is not limited to viruses
of this subtype or to other avian strains that may pose a pandemic
threat. CR6261 has been shown to recognize H1 viruses that have
emerged over a time span of 90 years from the H1N1 virus which
caused the 1918 ‘Spanish flu’ pandemic to the latest Brisbane
viruses. Since the epitope is conserved CR6261 is predicted to
bind to future antigenic drift variants. This means that CR6261
could be used to protect against all H1 influenza viruses, including
the ones resistant to oseltamivir. Use of CR6261 in combination
with effective medication against H3, such as oseltamivir or
zanamivir, would effectively protect against all seasonal influenza
viruses, without a need for prior knowledge of the virus subtype or
strain.
In the present study ferrets were challenged with an inoculum
which is probably much higher compared to the viral exposure in
naturally infection in humans. The rapid deterioration in ferrets
with death occurring within 3 days underpins this hypothesis since
humans exposed to H5N1 develop the first symptoms 2–4 days
after the last exposure and even periods of up to 8 days have been
reported [25]. The clinical signs in this model are quite extreme,
but important for establishing the efficacy of the antibody as proof
of concept. The data of these two experiments demonstrate the
prophylactic and therapeutic efficacy of this new class of human
monoclonal antibodies in a highly stringent and clinically relevant
ferret model of human influenza.
Materials and Methods
Antibody
The human monoclonal antibody CR6261 was isolated from
the IgM+, CD27+ B cell repertoire of a healthy individual who
was recently vaccinated with the seasonal influenza vaccine, using
phage display selection on recombinant H5 haemagglutinin [1].
CR3014, an isotype-matched antibody with the ability to
neutralize SARS corona virus–which has similar tissue/organ
tropism as that of H5 viruses–was used as a control antibody [32].
Both antibodies were produced on PER.C6H cells.
Animal Studies
The study was performed with outbred ferrets (Mustela putorius
furo, female, age approximately 8 months, Schimmel Farms,
Uddel, the Netherlands). Ferrets were screened for the presence of
serum antibodies against Aleutian Disease virus, circulating
seasonal influenza virus strains (A/H1N1, A/H3N2 and B) and
the challenge virus (H5N1, A/Indonesia/5/2005), and only
seronegative animals were used in the study. The animals were
housed in study groups of 6 (prophylactic experiment) or 10
(therapeutic experiment).
Antibodies were administered by intravenous injection in the
jugular vein. Viral challenge was performed intratracheally with
105 TCID50 A/Indonesia/05/2005 in 3 mL of PBS [33]. Clinical
observations were performed twice a day on days of intervention
and once daily on other days. In the prophylactic experiment,
animals were weighed 2 weeks before viral challenge (day 214),
immediately prior to antibody administration (day 21), and after
challenge (days 2, 4, and 5 or on the day of premature death). In
Efficacy of CR6261 in Ferrets
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the therapeutic experiment, animals were weighed on day 214
and day 22, immediately prior to challenge and antibody
administration, and on days 2, 4 and the last study day. Body
temperature was recorded every 15 minutes throughout both
experiments using a device (DST micro-T, Star-Oddi, Reykjavik,
Iceland) implanted in the peritoneal cavity 14 days before
challenge.
The animal experiments were carried out in the central animal
facilities of the Netherlands Vaccine Institute (NVI, Bilthoven)
under conditions that meet the Dutch legal requirements for
animal experimentation and are in accordance with the ‘Guide for
the care and use of laboratory animals’, the recommendations of
the Institute for Laboratory Animal Research (US National
Institutes of Health), and Association for Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC) standards.
Viral Shedding
Viral titrations were performed as described elsewhere [34].
Briefly, pharyngeal and nasal swabs were collected from all
animals at day 21, day 2, day 4, and day 5. Individual swabs were
homogenized and resuspended in 3 ml medium and stored at
280uC until analysis. Viral titres were determined by virus
titration on Madine Darby canine kidney (MDCK) cells. Viral
shedding from the upper respiratory tract was analysed by
calculating the proportion of ferrets with detectable levels of
infectious virus in nasal and/or throat swabs relative to the
number of living ferrets.
Viral Load
After necropsy, the cranioventral, craniodorsal, caudoventral
and caudodorsal sections of the right lung were collected from
each animal, weighed, homogenized and resuspended in 3 ml
medium, and stored at 280uC until analysis. Viral titres were
determined after thawing of the tissue sections followed by
homogenization and resuspension by virus titration on MDCK
cells. In addition, viral titres in tissues of brain, spleen, liver,
kidney, and plasma from animals that received either 30 mg/kg of
CR6261 or CR3014 one day prior to challenge were determined
using the same method.
Pathology
A complete macroscopic post-mortem examination was per-
formed on all animals. This included examination of the external
surfaces and all orifices; the thoracic, abdominal and pelvic cavities
with their associated organs and tissues; and the neck with its
associated organs and tissues. Lungs were weighed and all lung
lobes were inspected and lesions described. The left lung (including
trachea) was collected during autopsy, inflated with 10% neutral
buffered formalin for fixation/histology and microscopic exami-
nation. Paraffin embedded tissue sections (left cranial lobe, left
caudal lobe, right cranial-, middle- and caudal lobes and accessory
lobe) were stained with haematoxylin and eosin and assessed by
light microscopy for aspects like congestion, emphysema, presence
of foreign body, haemorrhagy, bronchioloalveolar hyperplasia and
inflammation, and oedema.
Anaesthesia
Prior to blood sampling, the taking of nose and throat swabs and
euthanasia, the ferrets were anaesthetised with ketamin (25 mg/
kg; i.m.). For implantation of temperature sensors, antibody
administration and viral challenge, the animals were anaesthetized
with a mixture of ketamin (12.5 mg/kg; i.m.) and domitor (7.5 mg/
kg; i.m.), followed by antisedan (0.5 mg/kg; i.m.).
Statistical Analyses
Survival times after viral challenge were analysed using the log-
rank test and survival proportions using the Fisher’s exact test.
Body weight expressed as percentage change from baseline was
calculated at the end of the study period (or earlier in the event of
earlier death). Maximum body temperatures were observed during
day one and these values were subsequently used for calculating
the mean maximum body temperature for each group. Variables
were analysed in an one-way analysis of variance (ANOVA) with
post-hoc testing to compare to the control group using Dunnett’s
adjustment for multiple comparisons.
Lung weight and lung viral titres were compared across arms
using ANOVA, with day of necropsy entered as a covariate.
Differences between treatment groups were estimated using
marginal means, with Sidak’s adjustment for multiple compari-
sons. Statistical analyses were performed using SPSS version 15.0
(SPSS Inc. USA). Statistical significance level was set at a= 0.05.
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